Navigation Links
New cell therapy a promising atherosclerosis treatment
Date:3/1/2011

Researchers at Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis. The new cell therapy, which is presented in the prestigious scientific journal Circulation, can open the way for new therapies for stroke and myocardial infarction if the results prove translatable to humans.

Atherosclerosis is a chronic inflammation of the blood vessels. Cholesterol is transported in the blood in particles called LDL ('bad' cholesterol) that can accumulate in the vessel walls. This triggers the body's immune system to react against LDL, which then cause inflammation in the vessels, and eventually thrombus formation. If such a thrombus forms in the coronary artery, the patient suffers a myocardial infarction; if it forms in the brain, a stroke can result.

The research group, under the direction of Professor Gran K Hansson at the Centre for Molecular Medicine, have developed a cell therapy that selectively dampens vascular inflammation induced by LDL. The therapy makes use of dendritic cells, which are characterized by a high degree of plasticity that renders them amenable to manipulation.

"With the appropriate treatment, dendritic cells can be made to inhibit rather than aggravate the inflammation around the LDL particles in the blood vessels," says Dr Andreas Hermansson, one of the researchers conducting the study. "A major advantage of this is that we can devise a treatment for vascular diseases that is highly specific."

The mouse studies now presented in Circulation have demonstrated substantial protective effects of the treatment, with a reduction of the atherosclerosis process of up around 70 percent. Last year, the researchers published results showing that antibodies recognizing the receptors that drive the immune reaction have protective effects, and now the same group is presenting a cell
'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Page: 1 2

Related biology news :

1. Why chemotherapy causes more infertility in women than in men
2. First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
3. Drug therapy shows significant benefit in treating a leading cause of childhood blindness
4. U of Alberta researcher discovers potential cancer therapy target
5. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
6. Photodynamic therapy against cancer
7. A loose grip provides better chemotherapy
8. Early tests find nanoshell therapy effective against brain cancer
9. New anti-HIV gene therapy makes T-cells resistant to HIV infection
10. Caffeine energizes cells, boosting virus production for gene therapy applications
11. Nanodisk gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... new mobile app has been launched this week to help ... the inner ear. The tool will allow sufferers of ... how they compare with people across the country. Mnire,s ... cause tinnitus, hearing loss, vertigo and a feeling of pressure ...
... January 29, 2014 The Genetics Society of ... Recipients. The five individuals honored are recognized by their ... community. "The 2014 GSA award winners are ... of genetics in research, in education, and in fostering ...
... 29, 2014 Myriad Genetics, Inc. (NASDAQ: MYGN) today ... with its Prolaris test, at the 2014 ASCO Genitourinary ... demonstrated the significant clinical value of Prolaris to physicians ... is a prognostic test that accurately predicts prostate cancer-specific ...
Cached Biology News:New app to monitor Ménière's Disease launched 2Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 2Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 3Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 4Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 5Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 6Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 7Genetics Society of America selects 5 geneticists to receive society's 2014 Awards 8Myriad's Prolaris significantly modifies treatment decisions for prostate cancer patients 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Oct. 5 C3i, the leader in technology services ... a leading global biopharmaceutical company, will deliver a joint ... newest version of Oracle Clinical/Remote Data Capture (OCRDC) software. ... Oracle Health Sciences User Group conference (OHSUG) in San ...
... Group, Inc. (OTC Bulletin Board: MDXG ), ... biomaterial-based products, announced today that its results for the ... before the opening of the market on Tuesday, October ... of its third quarter conference call on October 26, ...
... pressing concerns of the day, fear of plague probably isn,t ... whose responsibility it is to combat bioterrorism, plague is among ... like medical researcher Steve Smiley, whose lab at the Trudeau ... the public against weaponized forms of plague. The Institute, which ...
Cached Biology Technology:C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference 2MiMedx Group, Inc. Announces Release Date For Third Quarter Results 2Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3
... Microarrays designed for DNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... Aptamer Microarray contains greater than 1500 known ...
... Microarrays designed for DNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... synthesized on-chip and LC Sciences can provide ... are available as part of our comprehensive ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
Biology Products: